CRM Authors: Xenia von Wedel, Ian Khan, PR.com Newswire, Steve Mordue

News Feed Item

Algeta ASA Raises Euro 23 Million in Series A Round

Funds Support Continued Development of Alpharadin, Its Lead Cancer Therapeutic

OSLO, NORWAY -- (MARKET WIRE) -- 09/02/05 -- Algeta ASA, a therapeutics company dedicated to the development of novel anticancer agents based on alpha particle emitting radionuclides, announced today the closing of a Series A round of financing totaling NOK 185 million (Euro 23 million/US$29 million). The funds raised will support the continued development of the Company's lead product candidate, Alpharadin™, through its ongoing Phase II clinical trials and into pivotal Phase III trials as a potential new treatment for bone metastases arising from primary prostate cancer.

Alpharadin, is a novel bone-seeking experimental radiopharmaceutical based on the alpha particle emitter radium-223.

The syndicate of international investors included new investors HealthCap, Advent Venture Partners and SR One. Existing investors Selvaag Venture Capital, NorgesInvestor, Marlin Verdi AS and several smaller investors also participated in the round.

"We are very pleased to have attracted funding for our company from such an experienced, international group of investors, in addition to the continued support and commitment from our current investors. This is a strong endorsement for the company, its employees and the progress being made," says Dr. Thomas Ramdahl, CEO of Algeta. "With this strong financial base, we are now well placed to advance our lead product candidate, Alpharadin, through late-stage clinical trials towards commercialization, and to extend our development pipeline of new therapeutics based on our exciting alpha particle technology. We look forward to working with our new investors and greatly appreciate their experience and resources, which will assist our company going forward."

"Algeta's lead product candidate, Alpharadin, addresses a major market opportunity in the field of oncology. Bone metastases are a devastating consequence of the progression of certain cancers and current treatments are largely ineffective. HealthCap is very excited to be supporting the Algeta team in their efforts to develop new therapeutics that target this important unmet medical need," said Per Samuelsson, partner at HealthCap.

Concurrent with the financing, Per Samuelsson, Partner, HealthCap; Patrick Lee, General Partner, Advent Venture Partners; and Dr. Kent Gossett, Principal, SR One; will join Stein Annexstad, Managing Director, representing NorgesInvestor; Dr. Jens Petter Falck, Partner, Selvaag Venture Capital; and John Berriman, Chairman; on Algeta's Board of Directors.

Algeta was advised by BioScience Managers Limited (London, UK) during this financing round.

Notes to Editors

About Algeta ASA

Algeta ASA, headquartered in Oslo, Norway, is a private therapeutics company dedicated to the development of novel anticancer therapeutics based on alpha particle emitting radionuclides. The Company was founded in 1997 as Anticancer Therapeutic Inventions.

Algeta's lead product candidate, Alpharadin, is a novel bone-seeking experimental radiopharmaceutical based on the alpha particle emitter radium-223. Alpharadin is currently in Phase II clinical trials as a potential new treatment for bone metastases from prostate cancer.

An estimated 1.5 million patients worldwide suffer with bone metastases and there are approximately 300,000 new cases per year. Prostate and breast cancers account for more than 80% of all cases. Median survival for patients is three years and there are no effective therapies.

Alpha emitters have not until recently been a significant therapeutic modality. However, discoveries in radiochemistry and recent advances in the understanding of tumor and radiation biology led Algeta's scientific founders -- Roy Larsen and Oyvind Bruland -- to conceive how the unique features of alpha emitters, such as high potency and short range, could be exploited to create new therapeutic candidates promising unrivalled potency without unacceptable toxicities.

For more information, visit us at www.algeta.com.

For further information, please contact:
Dr. Thomas Ramdahl
Algeta ASA
+47 23 00 79 90

Mark Swallow PhD / Helena Podd
Citigate Dewe Rogerson
+44 (0)207 638 9571

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

IoT & Smart Cities Stories
Two weeks ago (November 3-5), I attended the Cloud Expo Silicon Valley as a speaker, where I presented on the security and privacy due diligence requirements for cloud solutions. Cloud security is a topical issue for every CIO, CISO, and technology buyer. Decision-makers are always looking for insights on how to mitigate the security risks of implementing and using cloud solutions. Based on the presentation topics covered at the conference, as well as the general discussions heard between sessio...
The platform combines the strengths of Singtel's extensive, intelligent network capabilities with Microsoft's cloud expertise to create a unique solution that sets new standards for IoT applications," said Mr Diomedes Kastanis, Head of IoT at Singtel. "Our solution provides speed, transparency and flexibility, paving the way for a more pervasive use of IoT to accelerate enterprises' digitalisation efforts. AI-powered intelligent connectivity over Microsoft Azure will be the fastest connected pat...
CloudEXPO has been the M&A capital for Cloud companies for more than a decade with memorable acquisition news stories which came out of CloudEXPO expo floor. DevOpsSUMMIT New York faculty member Greg Bledsoe shared his views on IBM's Red Hat acquisition live from NASDAQ floor. Acquisition news was announced during CloudEXPO New York which took place November 12-13, 2019 in New York City.
BMC has unmatched experience in IT management, supporting 92 of the Forbes Global 100, and earning recognition as an ITSM Gartner Magic Quadrant Leader for five years running. Our solutions offer speed, agility, and efficiency to tackle business challenges in the areas of service management, automation, operations, and the mainframe.
Apptio fuels digital business transformation. Technology leaders use Apptio's machine learning to analyze and plan their technology spend so they can invest in products that increase the speed of business and deliver innovation. With Apptio, they translate raw costs, utilization, and billing data into business-centric views that help their organization optimize spending, plan strategically, and drive digital strategy that funds growth of the business. Technology leaders can gather instant recomm...
In an age of borderless networks, security for the cloud and security for the corporate network can no longer be separated. Security teams are now presented with the challenge of monitoring and controlling access to these cloud environments, at the same time that developers quickly spin up new cloud instances and executives push forwards new initiatives. The vulnerabilities created by migration to the cloud, such as misconfigurations and compromised credentials, require that security teams t...
AI and machine learning disruption for Enterprises started happening in the areas such as IT operations management (ITOPs) and Cloud management and SaaS apps. In 2019 CIOs will see disruptive solutions for Cloud & Devops, AI/ML driven IT Ops and Cloud Ops. Customers want AI-driven multi-cloud operations for monitoring, detection, prevention of disruptions. Disruptions cause revenue loss, unhappy users, impacts brand reputation etc.
As you know, enterprise IT conversation over the past year have often centered upon the open-source Kubernetes container orchestration system. In fact, Kubernetes has emerged as the key technology -- and even primary platform -- of cloud migrations for a wide variety of organizations. Kubernetes is critical to forward-looking enterprises that continue to push their IT infrastructures toward maximum functionality, scalability, and flexibility. As they do so, IT professionals are also embr...
@CloudEXPO and @ExpoDX, two of the most influential technology events in the world, have hosted hundreds of sponsors and exhibitors since our launch 10 years ago. @CloudEXPO and @ExpoDX New York and Silicon Valley provide a full year of face-to-face marketing opportunities for your company. Each sponsorship and exhibit package comes with pre and post-show marketing programs. By sponsoring and exhibiting in New York and Silicon Valley, you reach a full complement of decision makers and buyers in ...
While the focus and objectives of IoT initiatives are many and diverse, they all share a few common attributes, and one of those is the network. Commonly, that network includes the Internet, over which there isn't any real control for performance and availability. Or is there? The current state of the art for Big Data analytics, as applied to network telemetry, offers new opportunities for improving and assuring operational integrity. In his session at @ThingsExpo, Jim Frey, Vice President of S...